Analgesics Market Size to Grow US$ 149.3 Billion By 2030

The global analgesics market size was valued at US$ 105.8 billion in 2021 and is anticipated to grow US$ 149.3 billion by 2030, registering a compound annual growth rate of 3.9% from 2022 to 2030.

The analgesics market report covering various industry elements and growth trends helpful for predicting the market’s future.

The study provides a strong base for the analgesics market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2030.

This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2022 to 2030. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the analgesics report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the analgesics market have been studied and analysed across many developments.

Analgesics Market Report Scope 

Also read: https://www.dailytechbulletin.com/dental-support-organizations-market/

Research Approach

The comprehensive report on the global analgesics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global analgesics market.

It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Key Players are  Abbott, Pfizer Inc., Eli Lilly & Company, Endo International plc, F. Hoffmann-La Roche AG Bausch Health Companies Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Johnson & Johnson Private Limited, GSK plc., Purdue Pharma L.P.

Analgesics Market Segmentations

By Drug Class

• Opioids
  • Morphine
  • Fentanyl
  • Codiene
  • Methadone
  • Meperidine
  • Oxycodone
  • Tramadol
  • Dextromethorphan
  • Buprenorphine
  • Others
• NSAIDs
• Local Anesthetics
• Acetaminophen

By Indication

• Surgical Pain
• Cancer Pain
• Neuropathic Pain
• Others

By Type

• Prescription
• OTC

By Pain Type

• Musculoskeletal Pain
• Surgical and Trauma Pain
• Cancer Pain
• Neuropathic Pain
• Migraine
• Obstetrical Pain
• Fibromyalgia
• Pain due to Burns
• Dental/Facial Pain
• Paediatric Pain
• Others

By Application

• Internal Analgesics
• External Analgesics

By Route of Administration

• Oral
• Parenteral
• Transdermal
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Drug Stores
• Online pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Analgesics Market, By Drug Class

7.1. Analgesics Market, by Drug Class, 2022-2030

7.1.1. Opioids

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. NSAIDs

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Local Anesthetics

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Acetaminophen

7.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Analgesics Market, By Indication

8.1. Analgesics Market, by Indication, 2022-2030

8.1.1. Surgical Pain

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Cancer Pain

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Neuropathic Pain

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Analgesics Market, By Type

9.1. Analgesics Market, by Type, 2022-2030

9.1.1. Prescription

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. OTC

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Analgesics Market, By Pain Type

10.1. Analgesics Market, by Pain Type, 2022-2030

10.1.1. Musculoskeletal Pain

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Surgical and Trauma Pain

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Cancer Pain

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Neuropathic Pain

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Migraine

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Obstetrical Pain

10.1.6.1. Market Revenue and Forecast (2017-2030)

10.1.7. Fibromyalgia

10.1.7.1. Market Revenue and Forecast (2017-2030)

10.1.8. Pain due to Burns

10.1.8.1. Market Revenue and Forecast (2017-2030)

10.1.9. Dental/Facial Pain

10.1.9.1. Market Revenue and Forecast (2017-2030)

10.1.10. Paediatric Pain

10.1.10.1. Market Revenue and Forecast (2017-2030)

10.1.11. Others

10.1.11.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Analgesics Market, By Application

11.1. Analgesics Market, by Application, 2022-2030

11.1.1. Internal Analgesics

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. External Analgesics

11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Analgesics Market, By Route of Administration

12.1. Analgesics Market, by Route of Administration, 2022-2030

12.1.1. Oral

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Oral

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Transdermal

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Others

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Analgesics Market, By Distribution Channel

13.1. Analgesics Market, by Distribution Channel, 2022-2030

13.1.1. Hospital pharmacies

13.1.1.1. Market Revenue and Forecast (2017-2030)

13.1.2. Retail pharmacies

13.1.2.1. Market Revenue and Forecast (2017-2030)

13.1.3. Drug Stores

13.1.3.1. Market Revenue and Forecast (2017-2030)

13.1.4. Online pharmacies

13.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 14. Global Analgesics Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.8. U.S.

14.1.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2. Europe

14.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.9. Germany

14.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.10. France

14.2.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.11. Rest of Europe

14.2.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.8. India

14.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.9. China

14.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.10. Japan

14.3.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.11. Rest of APAC

14.3.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.8. GCC

14.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.9. North Africa

14.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.10. South Africa

14.4.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.11. Rest of MEA

14.4.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.8. Brazil

14.5.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

Chapter 15. Company Profiles

15.1. Abbott

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Pfizer Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Eli Lilly & Company

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Endo International plc

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. F. Hoffmann-La Roche AG

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Bausch Health Companies Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Merck & Co. Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. AbbVie Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Novartis AG

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Johnson & Johnson Private Limited

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global analgesics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for analgesics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2282

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com